U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                 Amendment No. 1
                                       to
                                   Form 10-QSB

         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES  EXCHANGE ACT OF 1934

         For the quarter ended September 30, 1999

         Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

          New York                                  65-0565144
-------------------------------                  -------------------
(State or other jurisdiction of                  (I.R.S. Employer
incorporation or organization)                   Identification No.)

         2018 Oak Terrace
         Sarasota, Florida                       34231
 -------------------------------------          ----------
 (Address of principal executive offices)       (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:

                                                  Name of each exchange on
       Title of each class                          which registered

               None
-----------------------------                     -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:
                                    Mercedes Travis, Esq.
                                    Mintmire & Associates
                                    265 Sunrise Avenue, Suite 204
                                    Palm Beach, FL 33480
                                    Tel: (561) 832-5696
                                    Fax: (561) 659-5371


<PAGE>






     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                  Yes      X        No
                           ---            ---

         As of September 30, 1999,  there are 11,811,373  shares of voting stock
of the registrant issued and outstanding.




<PAGE>



                                     PART I

Item 1.   Financial Statements

<TABLE>
<S>                                                                        <C>
Condensed Balance Sheets as of September 30, 1999 and December 31, 1998    F-2

Condensed Statements of Operations for the Three and Nine Months Ended
September 30, 1999 and 1998                                                F-3

Statements of Cash Flows for the Nine Months Ended
September 30, 1999 and 1998                                                F-4

Notes to the Condensed Financial Statements                                F-6
</TABLE>











                                       -1-

<PAGE>






<TABLE>
<CAPTION>

                         SURGICAL SAFETY PRODUCTS, INC.
                            CONDENSED BALANCE SHEETS
                                   (Unaudited)

                                                      September        December
                                                          30              31,
                                                         1999            1998
                                                    --------------   ---------------
                  Assets
<S>                                                <C>                <C>
Current Assets
  Cash                                             $        12,970           41,191
  Accounts receivable                                       16,500            1,941
  Deposits                                                     750           58,700
  Inventory                                                  5,901            6,555
                                                    --------------     ------------
    Total current assets                                    36,121          108,387
                                                    --------------     ------------

Property and equipment, net                                201,151          112,772
                                                    --------------     ------------

Other Assets
  Intangible assets, net                                    44,139           49,232
  Software development costs, net                          131,444           92,873
  Other assets                                              10,250           10,250
                                                    --------------     ------------
    Total other assets                                     185,833          152,355
                                                    --------------     ------------

Total Assets                                       $       423,105          373,514
                                                    ==============     ============

Liabilities and Stockholders' Equity

Current Liabilities
  Line of credit                                   $        50,000    $
  Notes payable - related parties                           52,500
  Deferred revenue                                           6,874
  Accounts payable and accrued expenses                     72,005            55,331
    Total current liabilities                              181,379            55,331

Stockholders' Equity
  Common stock, $.001 par value,
    20,000,000 shares authorized;
    11,798,373 and 10,746,973 shares issued
    and outstanding in 1999 and 1998                        11,799            10,787
  Additional paid-in capital                             2,422,420         1,998,242
  Accumulated deficit                                  (2,192,493)       (1,690,846)
    Total stockholders' equity                             241,726           318,183

Total Liabilities and Stockholders' Equity         $       423,105    $      373,514
</TABLE>

   The accompanying notes are an integral part of these financial statements.
                                       F-2

                                       -2-

<PAGE>



<TABLE>
<CAPTION>

                         SURGICAL SAFETY PRODUCTS, INC.
                       CONDENSED STATEMENTS OF OPERATIONS

                                                  9 Months ended                               Three Months Ended
                                                   September 30,                                  September 30,
                                            1999                   1998                   1999                   1998
                                      ---------------------------------------       ---------------------------------------
<S>                                   <C>                    <C>                    <C>                    <C>
Revenue
   Net sales                          $           720        $           797        $           240        $           355
   Leasing and other fees                     162,577                 38,007                111,264
   Other                                        1,924                  6,910                    984                  6,059
income
    Total revenue                             165,221                 45,714                112,488                  6,414

Costs and expenses
  Cost of medical products sold                14,271                  1,966                  5,866                    687
  Operating expenses                          602,555                497,649                207,321                174,867
  Research and development expenses            40,287                                        20,202
  Interest expense                              9,755                 13,639                  2,315                    186
    Total costs                               666,868                513,254                235,704                175,740

Net loss before income taxes                 (501,647)              (467,540)              (123,216)              (169,326)

Provision for income taxes

Net loss                              $      (501,647)       $      (467,540)       $      (123,216)       $      (169,326)

Net loss per share                    $        (0.045)       $        (0.045)       $        (0.010)       $        (0.016)
</TABLE>

                 The accompanying notes are an integral part of
                          these financial statements.

                                       F-3



                                       -3-

<PAGE>



<TABLE>
<CAPTION>

                         SURGICAL SAFETY PRODUCTS, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

                                                                           Nine months ended
                                                                             September 30,
                                                                      1999                1998
                                                            --------------------------------------------
Cash Flows From Operating Activities
<S>                                                         <C>                     <C>
  Net loss                                                  $       (501,647)       $       (467,540)
  Adjustments to reconcile net loss to cash
    used in operating activities
      Depreciation and amortization                                   86,680                  24,562
      Common stock issued for services and
           employee compensation                                      41,303                 141,875
      Stock option compensation expense                              (91,113)
      Decrease (increase) in operating assets
        Receivables                                                  (14,559)                248,487
      Inventory                                                          654                  (6,885)
  Increase (decrease) in operating liabilities
         Deferred revenue                                              6,874
    Accounts payable and accrued expenses                             16,674                 (45,161)
          Total adjustments                                           46,513                 362,878
            Net cash used in operating activities                   (455,134)               (104,662)

Cash Flows From Investing Activities
  Furniture and equipment purchased                                  (93,239)                (61,195)
  Software development additions                                     (57,348)                (67,528)
    Net cash used in investing activities                           (150,587)               (128,723)

Cash Flows From Financing Activities
  Proceeds from related party loans                                   77,500
  Advances/(repayments) on line of credit,                            50,000                (100,000)
net
  Repayment of stockholder loans                                     (25,000)               (233,720)
  Proceeds from issuance of common stock                             475,000                 939,000
    Net cash provided by financing activities                        577,500                 605,280

Net increase (decrease) in cash                                      (28,221)                371,895
Cash at beginning of year                                             41,191                       -
Cash at end of year                                        $          12,970       $         371,895

Supplemental Cash Flow Information:
  Cash paid for interest                                   $           5,474       $          31,678
</TABLE>

   The accompanying notes are an integral part of these financial statements.
                                       F-4


                                       -4-

<PAGE>





For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.

Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

For the Nine Months Ended September 30, 1999
  The Company  received  fixed  assets in the amount of $58,700 for which it had
    recorded deposits of such amount at December 31, 1998.

For the Nine Months Ended September 30, 1998
  TheCompany  issued  common  stock  for  prepaid  legal  and  public  relations
     services in the amount of $47,500 as of September 30, 1998




   The accompanying notes are an integral part of these financial statements.
                                       F-5


                                       -5-

<PAGE>



Notes to the Condensed Financial Statements
Note 1 - Account Policies

Basis of Presentation
The condensed financial  statements of Surgical Safety Products,  Inc. (Company)
have been prepared  without audit,  pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. These consolidated financial statements should be read in
conjunction  with the  financial  statement  and notes  thereto  included in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1998.

The results of operations for the nine month period ended September 30, 1999 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management  the  accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present fairly the financial position as of September
30, 1999, the results of operations and cash flows for the three and nine months
ended September 30, 1999 and September 30, 1998.

Net Loss Per Share
Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) no. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents  have not been include in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.

Reclassifications
Certain   reclassifications  have  been  made  in  the  prior  year's  financial
statements to conform to the current period presentations.

Note 2 - Stock Compensation Expense
During fiscal year 1998, the Company issued stock options with an exercise price
that was below  market to certain of its  employees.  Accordingly,  the  Company
recorded  $91,113 of  compensation  expense related to the issuance for the year
ended December 31, 1998.

In the first  quarter of 1999,  the Company  canceled  these  stock  options and
issued  options with an exercise  price above that of market.  Accordingly,  the
Company  decreased its payroll expenses by $91,113 for the cancellation of these
options for the nine months ended  September 30, 1999.  In addition,  during the
nine months ended  September 30, 1999, the Company issued common stock valued at
$39,053 to certain of its employees and $7,500 to certain consultants in lieu of
cash  compensation  for services.  The common stock was valued based on the fair
market value for the shares on the dates the compensation would have been paid

                                       F-6

                                       -6-

<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     On July 30, 1999,  the Company  entered into a long term  agreement with US
Surgical  which  is  a  private  partner  network   agreement  (the  "Long  Term
Agreement"). Under the Long Term Agreement, Surgical agreed to sell four hundred
(400)  licenses for the use of one or more OASiS systems and US Surgical  agreed
to nominated four hundred (400) hospitals for such licenses. Each license is for
a term of three (3) years  commencing with  "substantial  installation"  of such
unit. "Substantial installation" is defined as delivery of the OASiS unit to the
hospital and connection to the Internet.

     Under the terms of the Long Term  Agreement,  US Surgical must purchase two
hundred (200) licenses within the first year, and subject to certain obligations
on the part of  Surgical to license  units to third  parties,  must  purchase an
additional two hundred (200) licenses by the end of the second year.  Hospital s
with units  installed  under the Short Term  Agreement  are  counted  toward the
minimum  number of  hospitals  required.  On August 10,  1999 US  Surgical  paid
Surgical  $100,000.00 as a  non-refundable  down payment for such licenses.  The
first 200 licenses are an  additional  $1,500 each and  subsequent  licenses are
$1,000 each.

     The Long Term Agreement  further  provides that neither  Surgical,  nor any
third  party  other  than US  Surgical,  may  place  OASiS  units  in any of the
"protected  departments"  of the  hospitals,  unless  it is  installed  prior to
receipt of a purchase  order from US  Surgical  or unless US  Surgical  does not
exercise  its  right  of first  refusal  after  notice  from  Surgical  for such
hospital.  The Long Term Agreement defines "protected  departments" as Operating
Room,  Labor  and  Delivery,  Emergency  Room,  Ambulatory/Same  Day  Surgery  /
Outpatient,  Nuclear Medicine,  Intensive Care, Orthopedic / Ortho Casting Room,
and Dialysis. US Surgical is required to have each hospital bear the entire risk
of loss  and  damage  to any  OASiS  system  except  if such  is  caused  by the
negligence or wilful misconduct of Surgical.  US Surgical must maintain casualty
insurance  in amounts  and with  companies  acceptable  to Surgical on the OASiS
units and its related amenities with Surgical as the loss payee. US Surgical may
elect to have the OASiS systems  installed in hospitals it nominates  co-branded
with its name.  Surgical  has the  discretion  to select  the  content,  related
services and in- service  products for the OASiS  systems  installed  under this
agreement; however, during the term of the agreement, US Surgical is required to
pay for and maintain a minimum of one hundred  forty (140)  product  in-services
modules  in an  average of at least 80% of all OASiS  systems  installed  in the
United  States  whether or not covered by this  agreement and 100% on those that
are covered by the agreement.  US Surgical's  product-based  modules produced by
Surgical  become the  property  of US  Surgical.  Surgical  retains the right to
display such modules on other OASiS units. All other modules remain the property
of Surgical.  Surgical receives a fee for production of the modules. If Surgical
installs additional OASiS units in a designated hospital, US Surgical receives a
10% commission.  Surgical  receives a monthly  maintenance fee for each unit, of
$149,  unless  paid a year in advance in which case it may be  discounted  up to
10%.

     In July 1999, the Company  executed a Consulting  and Assistance  Agreement
with Triton Capital,  Inc.,  a  Florida corporation ("Triton").  Under the terms

                                                        -7-

<PAGE>



of this  agreement,  Triton has been  engaged to identify  sources of capital or
potential business relationships and to assist the Company in (i) raising equity
or debt financing in the amount of $6,000,000 (ii) arranging for trade financing
for production, sale, lease, rental or other disposal of the Company's products;
and (iii) arranging for the sale, merger, or consolidation of the Company or for
joint ventures or strategic  alliances  with other  appropriate  business.  This
agreement is non-exclusive.  In the event Investment  Financing is secured,  the
Company was to pay compensation equal to 8% for any investment  financing to the
person or entity  placing  such  investment;  provided  such person or entity is
qualified to receive such compensation in the state of residence of the investor
and will issue warrants to purchase restricted Common Stock in the Company in an
amount equal to 100,000 for every $1 million funded, exercisable for a period of
five (5) years at a price equal to the closing bid price of the Company's shares
on  the  date  of  such  funding  and  which  warrants  are to  have  piggy-back
registration  rights and cashless  exercise  provisions.  The Company is free to
reject any offered  financing or  arrangements;  however,  in the event that the
Company  enters any  arrangement  within 180 days of its written  rejection,  on
terms less  favorable  to the  Company,  Triton is to receive a flat fee. In the
event the  Company  "shops"  any  offer of  financing  presented  to it to other
potential  sources and  accepts  such other  financing,  Triton is entitled to a
success fee. Triton is to be reimbursed pre-approved disbursements and expenses.
The  agreement  provides for  confidentiality  and  cross-indemnification  . The
agreement is subject to  cancellation by either party with five (5) days written
notice.  Any  disputes  under the  agreement  are  required to be  submitted  to
arbitration,  with  costs  payable by the losing  party.  No funding  under this
agreement has been received as of the date hereof.

Discussion and Analysis

     The  Company  was  founded  in 1992  to  combat  the  potential  spread  of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

     The  Company  was in  the  development  stage  until  1993  when  it  began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  1998,  the  Company  generated  revenues of
approximately  $1,100,000  from a limited number of customers.  Since  inception
through  December  31,  1998,  the Company has  generated  cumulative  losses of
approximately  $1,690,000.  Although the Company has  experienced  a significant
percentage  growth in revenues from fiscal 1992 to fiscal 1998, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results,
especially  in  light  of  the  contract  with  US  Surgical  to  assist  in the
introduction  of OASiS.  Due to the  Company's  operating  history  and  limited
resources,  among other factors, there can be no assurance that profitability or
significant  revenues on a quarterly  or annual  basis will occur in the future.
Moreover,  the Company expects to continue to incur operating  losses through at
least the first half of 2000, and there can be no assurance that losses will not
continue after such date. The Company had  commitments  for  installations  in a
total of 12 hospitals on or before June 30,  1999,  ten of which  related to the
agreement  with  US  Surgical  and  two  are a  result  of the  Company's  sales
department.  As of the date hereof the Company has  completed  installations  of
fourteen  (14)  units in seven  (7)  hospitals,  five (5) of which are under the
original  agreement with US Surgical.  Installation of the remaining units under
the US Surgical initial agreement have been merged into the Long Term Agreement.

                                       -8-

<PAGE>



     As discussed in the  independent  auditors'  report,  the operating  losses
incurred  by the  Company  raise  doubt about its ability to continue as a going
concern. In addition,  with the implementation of its agreement with US Surgical
and in the event of the  reactivation  of its  various  distribution  agreements
and/or with the establishment of one or more strategic  alliances in addition to
US  Surgical,  the  Company  expects to  experience  a period of  growth,  which
requires it to significantly increase the scale of its operations. This increase
will  include the hiring of  additional  personnel  in the areas of (i) customer
service to provide technical  support for the hospitals where  installations are
located and (ii) technical staff to make changes  requested by those  hospitals.
This will result in  significantly  higher operating  expenses.  The increase in
operating  expenses  is  expected  to be  partially  funded  by an  increase  in
revenues. However, the Company's net loss may continue to increase. Expansion of
the  Company's  operations  may  cause a  significant  strain  on the  Company's
management,  financial  and other  resources.  The  Company's  ability to manage
recent and any  possible  future  growth,  should it occur,  will  depend upon a
significant  expansion of its sales and  marketing,  research  and  development,
accounting  and other internal  management  systems and the  implementation  and
subsequent improvement of a variety of systems,  procedures and controls.  There
can be no assurance that significant problems in these areas will not occur. Any
failure to expand these areas and implement and improve such systems, procedures
and  controls in an efficient  manner at a pace  consistent  with the  Company's
business  could  have a  material  adverse  effect  on the  Company's  business,
financial  condition  and results of  operations.  As a result of such  expected
expansion and the anticipated increase in its operating expenses, as well as the
difficulty in forecasting  revenue  levels,  the Company  expects to continue to
experience  significant  fluctuations in its revenues,  costs and gross margins,
and therefore its results of operations.

     The Company's  plan of operations for the next twelve months is to focus on
building  revenue from the  installation  of the OASiS  system in the  hospitals
designated by US Surgical and to install  additional  OASiS systems in hospitals
not  under  the US  Surgical  agreement  but with  whom the  Company  has  begun
negotiations and in some cases reached a commitment.  Additionally,  the Company
intends to install the  inservice  modules  from US Surgical  and other  medical
product  manufacturers  at both the US  Surgical  and the other  hospitals.  The
Company also is aggressively  seeking strategic alliances with targeted industry
partners such as  manufacturers of devices,  manufacturers  of  pharmaceuticals,
professional  organizations  such as nursing  associations  and  hospital  group
purchasing organizations and integrated health networks.

     The Company  estimates  that  revenues  will be  sufficient to fund ongoing
operations at the current level when the number of OASiS  installations  reaches
approximately  100 to 125 and the total  number  of  inservice  modules  reaches
approximately  150.  The  Company  has  purchased  20  OASiS  units  from  Kiosk
Information  Systems,  Inc.,  of which eleven (11) were  installed  under the US
Surgical  agreements and at St.  Francis  Hospital.  The Company  already has 32
inservice  modules under the US Surgical  agreement  and is in  discussion  with
various  manufacturers  interested  in using OASiS to inservice  more than 50 of
their  products.  The Company  believes  that each of the initial  installations
should have a position as to long term  acceptance  within  three (3) to six (6)
months and that this initial time is the test period to determine  the potential
for market  acceptance at that  hospital.  In the case of US Surgical  hospitals
under the initial agreement, this period was nine (9) months by contract. At the
end of such test  period,  the  Company  believes  it will be in a  position  to
execute  three (3) year  leases and  finance  such  leases  through a  leveraged
leasing arrangement with Rockford or a similar funding source.

                                       -9-

<PAGE>



     In the short term, to fund operations through the fourth quarter, 1999, the
Company will be required to seek additional funds from strategic  alliances with
potential  clients,  its shareholders,  from additional third party financing or
seek third  party  debt or equity  financing  other  than  those  planned by the
current anticipated private placement.  Currently, the Company has exhausted its
existing  lines of  credit.  Therefore,  the  Company  has  begun to scale  back
operations.  The Company is exploring a program to substitute  stock for cash in
its compensation program. In addition,  immediate focus is being placed on other
methods to reduce its breakeven  point,  such as staffing cuts, or the licensing
or sale of some of the  Company's  assets  or  product  lines to third  parties.
Provided that  additional  funding or its scale back is successful,  the Company
believes that it can meet its capital  needs  through year end.  There can be no
assurance that the Company will be successful in these efforts.

     As  discussed  in Note 10 to the  Financial  Statements,  if the  financing
referred to above is not  secured,  the  recoverability  of the  recorded  asset
amounts may be impaired.

     In 2000,  the Company will require  between $8 and $9 million in additional
capital  in the form of debt or equity to fund the  continued  expansion  of the
OASiS system and its  development to meet increased  demand and to implement its
plans for increased  marketing of its medical device  products.  The Company has
met with several venture capital firms, investment bankers,  factoring companies
and traditional lending sources,  each of whom have expressed early interest and
many of whom are awaiting the conclusion of the testing period.  The Company has
accepted no definite  offer,  with the exception of the short term funding being
sought through Triton.  There can be no assurance that such long-term  financing
will be  available  to the  Company or that it will be on terms that the Company
may seek.

Results of Operations for the Three and Nine Months Ended September 30, 1999 and
1998

Overview

     From its inception, the Company has incurred losses from operations.  As of
September 30, 1999, the Company had cumulative net losses totaling approximately
$2,192,493. Through fiscal 1998, the Company focused primarily on the design and
development of its propriety products, as well as providing consulting services.
During fiscal 1999,  management shifted its focus to aggressively  marketing its
proprietary products.

Financial Position

     Working  capital as of  September  30, 1999 was a deficit of  $145,258,  as
compared to working  capital of $53,056 at December 31, 1998.  This  decrease is
primarily  due to  additional  borrowings  on the  Company's  line of credit and
increases in Notes payable-related parties, the transfer of deposits to property
and equipment and the reduction in cash.

Revenues


                                      -10-

<PAGE>



     For the three months  ended  September  30, 1999 and 1998,  the Company had
total revenues of $112,488 and $6,414, respectively.  For the three months ended
September 30, 1999,  revenues were comprised  primarily of the initial  payments
received from US Surgical  associated with the Long Term Agreement and for Oasis
unit rentals.  For the nine months ended September 30, 1999, total revenues were
$165,221  compared  to $6,413 in the same  period  last year.  The  increase  of
$140,130 or 574% is due to revenue from the 1999 launch of Oasis. In 1998, Oasis
was still under development.

Selling, General, and Administrative Expenses

     For the nine months ended September 30, 1999,  operating expenses increased
by $104,906 or 21% from  $497,649 for the nine months ended  September 30, 1998.
This increase is primarily related to marketing support  expenditures to sustain
the launch of the  Company's  Oasis  system.  In  accordance  with the Company's
marketing plan for fiscal 1999, expenses related to promotion,  trade shows, and
conventions  were  increased to enhance the industry  awareness of the company's
products and services.

     In the past,  the  Company  has  focused on the design and  development  of
proprietary  products.  For fiscal 1999,  the Company has launched an aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical believes that the increased operating expenses incurred during the nine
months ended September 30, 1999 will position the Company to generate  increased
revenue in the 2000 fiscal year.

Liquidity and Capital Resources

     The financial  condition,  liquidity  and capital  resources of the Company
should be assessed  in context  with the ability of the Company to continue as a
going concern as discussed in the independent auditors' report.

     The  Company's  operations  have been funded  primarily  from the  $475,000
proceeds of the private placement  completed in the second quarter 1999 and from
cash flow of $102,500 from shareholder  loans and advances on the line of credit
during the nine months ended  September  30,  1999.  This allowed the Company to
purchase capital assets, enhance its OASiS software and fund current operations.
At September 30, 1999, the Company has a $11,220 cash position.

     The Company has a line of credit in the amount of $100,000  that expires in
May 2017 and is guaranteed by Dr. Swor and his wife. The line of credit also has
been used to fund  operations  on a  short-term  basis and $100,000 is currently
outstanding.

     Net cash used for  investing  for the nine months ended  September 30, 1999
was  approximately  $150,587,  representing  primarily OASiS units purchased and
costs related to the new version of OASiS which have been capitalized.

     In the short term, to fund operations through the fourth quarter, 1999, the
Company will be required to seek additional funds from strategic  alliances with
potential  clients,  its shareholders,  from additional third party financing or
seek third  party  debt or equity  financing  other  than  those  planned by the


                                      -11-

<PAGE>



anticipated private placement. Currently, the Company has exhausted its existing
lines of credit. Therefore, the company has begun to scale back operations.  The
company is exploring  programs to substitute  stock for cash in its compensation
programs.  In  addition,  immediate  focus is being  placed on other  methods to
reduce its  breakeven  point,  such as staffing cuts or the licensing or sale of
some of the Company's  assets or product lines to third  parties.  Provided that
additional  funding is secured  and its scale back is  successful,  the  Company
believes that it can meet its capital  needs  through year end.  There can be no
assurance that the Company will be successful in these efforts.

Impact of the Year 2000 Issue

     The Year 2000  Issue is the  result of  potential  problems  with  computer
systems or any equipment  with computer  chips that use dates where the date has
been stored as just two digits (e.g. 98 for 1998). On January 1, 2000, any clock
or date recording  mechanism  including date sensitive  software which uses only
two digits to represent  the year,  may  recognize the date using 00 as the year
1900  rather  than the year  2000.  This  could  result in a system  failure  or
miscalculations causing disruption of operations,  including among other things,
a temporary  inability  to process  transactions,  send  invoices,  or engage in
similar activities.

     Management has reviewed its current  internal systems and is in the process
of  upgrading  its  accounting  system to be Year 2000  compliant.  The  Company
purchased new hardware in 1998 that is Year 2000 compliant. Its internal systems
are Year 200 compliant and the Company expects the testing of such systems to be
completed in the fourth  quarter of 1999.  Management  does not  anticipate  any
significant  additional  costs that would  relate to  upgrading  its  systems to
support the Year 2000.

     Further,  management  does  not  believe  the Year  2000  will  impact  the
operation  of the OASiS  system since the software for this system does not rely
on legacy  applications or subsystems.  OASiS is designed to handle dates in the
form of a two digit month and day and a four digit year,  thus avoiding the Year
2000 problem

     The  Company  believes  that  it has  disclosed  all  required  information
relative to Year 2000 issues relating to its business and  operations.  However,
there can be no  assurance  that the  systems  of other  companies  on which the
Company's  systems rely also will be  converted  in a timely  manner or that any
such failure to convert by another  company would not have an adverse  affect on
the Company's business, operations or financial condition.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital  expenditures  (including the amount and nature thereof),  demand
for the Company's  products and services,  expansion and growth of the Company's
business and operations, and other such matters are forward-looking  statements.

                                      -12-

<PAGE>



These  statements  are based on certain  assumptions  and  analyses  made by the
Company in light of its  experience  and its  perception of  historical  trends,
current conditions and expected future  developments as well as other factors it
believes are appropriate in the circumstances.  However,  whether actual results
or developments will conform with the Company's  expectations and predictions is
subject  to a number of risks and  uncertainties,  general  economic  market and
business  conditions;  the business  opportunities (or lack thereof) that may be
presented  to and pursued by the  Company;  changes in laws or  regulation;  and
other   factors,   most  of  which  are  beyond  the  control  of  the  Company.
Consequently, all of the forward-looking statements made in this Form 10-QSB are
qualified by these cautionary  statements and there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected consequence to
or effects on the Company or its business or operations.

                                     PART II

Item 1.  Legal Proceedings.

     The  Company  knows  of no legal  proceedings  to which it is a party or to
which any of its  property is the  subject,  which are  pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.

Item 2. Changes in Securities and Use of Proceeds

     None

Item 3. Defaults in Senior Securities

     None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matter was  submitted  during the quarter  ending  September  30,  1999,
covered by this  report to a vote of the  Company's  shareholders,  through  the
solicitation of proxies or otherwise.

Item 5. Other Information

     None

Item 6. Exhibits and Reports on Form 8-K

     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:



                                      -13-

<PAGE>



Exhibit No.    Description
-----------    --------------------------------
3.(I).1        Articles of Incorporation of Surgical Safety Products, Inc., a
               Florida corporation filed May 15, 1992 [1]

3.(I).2        Articles of Amendment filed December 9, 1992 [1]

3.(I).3        Articles of Amendment filed July 19, 1994 [1]

3.(I).4        Articles of Amendment filed October 11, 1994 [1]

3.(I).5        Articles of Incorporation of Sheffeld Acres, Inc., a New York
               Corporation filed May 7, 1993 [1]

3.(I).6        Articles of Merger filed in the State of Florida
               October 12, 1994 [1]

3.(I).7        Certificate of Merger filed in the State of New York
               February 8, 1995 [1]

3.(I).8        Certificate to Do Business in the State of Florida
               filed April 11, 1995 [1]

3.(I).9        Certificate of Amendment filed May 1, 1998 [1]

3.(II).1       Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety
               Products, Inc. [1]

3.(II).2       Amended Bylaws of Surgical Safety Products, Inc. [2]

10.1           Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE
               dated December 8, 1997 [1]

10.2           Prepaid Capital Lease Agreement with Community Health Corporation
               relative to Sarasota Medical Hospital OASiS Installation dated
               January 30, 1998 [1]

10.3           Letter of Intent with United States Surgical Corporation
               dated February 12, 1998 [1]

10.4           Form of Rockford Industries, Inc. Rental Agreement and Equipment
               Schedule to Master Lease Agreement [1]

10.5           Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6           Distribution Agreement with Morrison International Inc.
               dated September 30, 1996 [1]

10.7           Distribution Agreement with Hospital News
               dated August 1, 1997 [1]


                                      -14-

<PAGE>



10.8           Clinical Products Testing Agreement with Sarasota Memorial
               Hospital dated January 30, 1998 [1]

10.9           Real Estate Lease for Executive Offices effective
               June 1, 1998 [1]

10.10          Employment Agreement with Donald K. Lawrence dated
               April 1, 1997 [1]

10.11          Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12          Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13          Agreement for Consulting Services with Stockstowatch.com Inc.
               dated March 30, 1988 [1]

10.14          Form of Employee Option Agreement dated July 1994 [1]

10.15          Form of Employee Option Agreement dated 1998 [1]

10.16          Form of Consultants Option Agreement dated July 1994 [1]

10.17          Form of Consultants Option Agreement dated 1998 [1]

10.18          Confidential Private Offering Memorandum dated May 30, 1995 [1]

10.19          Supplement to Private Offering Memorandum dated
               October 30, 1995 [1]

10.20          Stock Option Agreement with Bay Breeze Enterprises LLC dated
               April 9, 1998 [1]

10.21          Revolving Loan Agreement, Revolving Note, Security Agreement with
               SouthTrust Bank dated May 2, 1997 [1]

10.22          Agreement between the Company and T. T. Communications, Inc.
               dated October 15, 1998 [2]

10.23          Agreement between the Company and U.S. Surgical Corporation dated
               October 28, 1998. [2]

10.24          Collaborative Agreement between the Company and Dr. William B.
               Saye dated November 16, 1998. [2]

10.25          Kiosk Information System, Inc. Purchase Order dated
               November 3, 1998 [2]

10.26          Surgical Safety Products 1999 Stock Option Plan adopted
               January 1999 [2]


                                      -15-

<PAGE>



10.27          Form of the Employee Option Agreement under the Surgical Safety
               Products 1999 Stock Option Plan dated January 1999 [2]

10.28          Form of the Director, Consultant and Advisor Option Agreement
               under the Surgical Safety Products 1999 Stock Option Plan dated
               January 1999 [2]

10.29          Verio, Inc. Access Service Agreement dated February 16, 1999. [2]

10.30          Form of Investor Subscription Documents and Agreements relative
               to the April 1999 Self Directed Private Placement Offering under
               Rule 506 of Regulation D. [3]

10.31          Form of the Warrant issued pursuant to the April 1999 Self
               Directed Private Placement Offering under Rule 506 of
               Regulation D. [3]

10.32          Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33          Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34          Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35          Private Partner Network Agreement dated July 30, 1999 with
               US Surgical [5]

10.36          Staff/Client Leasing Agreement dated October 16, 1999, as amended
               September 15, 1999 [5]

10.37          Agreement dated July 15, 1999 with Triton Capital Inc.[6]

27.1 *         Financial Data Sheet
----------------
[1] Previously filed with the Company's Form 10SB
[2] Previously filed with the Company's Amendment No. 1 to the Form 10SB
[3] Previously filed with the Company's Form 10QSB for the Quarter ended
    March 30, 1999
[4] Previously filed with the Company's Form 10QSB for the Quarter ended
    June 30, 1999
[5] Previously filed with the Company's Amendment No. 2 to the Form 10SB
[6] Previously filed with the Company's Form 10QSB for the Quarter ended
    September 30, 1999

* Filed Herewith
----------------

                       (b) No Reports on Form 8-K were filed  during the quarter
ended September 30, 1999.

                                      -16-

<PAGE>




                                   SIGNATURES

      In accordance with Section 12 of the Securities  Exchange Act of 1934, the
registrant caused this Registration  Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                Surgical Safety Products, Inc. (Registrant)

Date: December 27, 1999
                                By:/s/ Frank M. Clark
                                   ------------------------
                                   Frank M. Clark, President and CEO

                                By:/s/ Donald K. Lawrence
                                   -----------------------
                                   Donald K. Lawrence
                                   Vice President and Secretary

                                By:/s/ G. Michael Swor
                                   ----------------------
                                   G. Michael Swor
                                   Treasurer

                                By:/s/ David Collins
                                   ----------------------
                                   David Collins
                                   Acting Chief Financial Officer


[sign page SSP 10QSB/A 9.30.99]
                                      -17-